Stay updated with breaking news from Upjohn Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW YORK, March 11, 2024 /PRNewswire/ -- IN THE COURT OF COMMON PLEAS OF ALLEGHENY COUNTY, PENNSYLVANIA RAJESH PATEL, Individually and on Behalf of All Others Similarly...
Reaffirms 2022 Guidance Ranges [1] Across Total Revenues, Adjusted EBITDA and Free Cash Flow; Driven by Solid Operating Momentum Despite Foreign Exchange...
Strategic Update: Our Path to Return to Growth November 7, 2022 Forward Looking Statements ... | November 7, 2022
/PRNewswire/ -- First-Quarter 2022 Results Reflect Strong Operational Start to the Year Total Revenues Were $4.19 billion U.S. GAAP Net Earnings Were $399.2...
5% Below are specific updates on pipeline assets since our previous earnings announcement on October 27, 2020: Abrocitinib (PF-04965842) — In November 2020, Pfizer announced positive top-line results from the fifth Phase 3 trial of abrocitinib, JADE REGIMEN, a 52-week study which investigated abrocitinib in patients 12 and older with moderate to severe atopic dermatitis (AD) following response to initial open label induction treatment with abrocitinib 200 mg. Patients were randomized into one of three arms: 200 mg, 100 mg or placebo. Both doses of abrocitinib met the primary endpoint, resu...